ANKRD29 (ankyrin repeat domain 29) is a protein-binding gene located on chromosome 18 that functions as a tumor suppressor and diagnostic biomarker across multiple cancer types. In non-small cell lung cancer (NSCLC), ANKRD29 expression is frequently decreased due to promoter hypermethylation 1. High ANKRD29 expression correlates with better clinical outcomes and inhibits cell proliferation and migration by regulating the MAPK signaling pathway 1. ANKRD29 enhances T cell killing ability and predicts immunotherapy response in NSCLC 1. ANKRD29 serves as a shared diagnostic biomarker between periodontitis and breast cancer, likely mediating immune cell regulation in both diseases 2. In platinum-resistant lung adenocarcinoma, ANKRD29 depletion in stromal areas correlates with drug resistance; its overexpression sensitizes cells to cisplatin 3. Within a five-gene predictive signature for platinum resistance, ANKRD29 achieved exceptional diagnostic accuracy (AUC=0.9639) 3. ANKRD29 also appears relevant in epilepsy and glioma pathology, where it features in both diagnostic and prognostic models 4. Clinically, ANKRD29 represents a promising biomarker for cancer prognosis, immunotherapy response prediction, and drug susceptibility evaluation. Its tumor-suppressive functions and involvement in immune regulation position it as a potential therapeutic target, though further mechanistic studies are warranted.